Can Your Neutrophil Count Predict Diabetes Diet Response?

Your CBC may contain a diabetes clue that most people never discuss: the absolute neutrophil count. In one long-term dietary trial of people with coronary heart disease, lower baseline neutrophils predicted less type 2 diabetes, while higher counts predicted poorer odds of remission after diabetes had developed. The signal appeared only with a Mediterranean diet, not a low-fat diet. That is interesting. It is also far from a clinical rule.

The Mediterranean diet itself has a much broader evidence base for diabetes prevention and metabolic health. The unsettled question is whether neutrophils help explain who benefits most—or merely track other changes, especially weight loss and inflammation.

A routine immune marker predicted diabetes risk in CORDIOPREV

Neutrophils are white blood cells that help fight infection. They also rise with many ordinary conditions, including acute illness, smoking, chronic inflammation, and some medications. A high result on a CBC therefore does not diagnose metabolic disease, and it does not tell you why the count is high.

Still, a 2025 CORDIOPREV analysis found a notable association. Researchers followed 462 participants with coronary heart disease who did not have type 2 diabetes at baseline for 60 months; 107 developed diabetes. Participants had been randomized to a Mediterranean diet or a low-fat diet. After adjustment for clinical covariates, those in the lowest baseline-neutrophil tertile had a lower diabetes incidence than those in the highest tertile (hazard ratio 0.442, 95% confidence interval 0.255 to 0.768).

In the Mediterranean-diet arm, the lowest versus highest tertile comparison had a hazard ratio of 0.371 (95% CI 0.182 to 0.762). The association was statistically significant in that arm and not in the low-fat arm. A prediction model that included neutrophil count had an area under the curve of 0.711 (95% CI 0.652 to 0.769), and the investigators identified neutrophil count as its most important variable.

Those figures describe relative risk within this study population, not an individual forecast. The study does not provide a validated neutrophil threshold that someone can apply to a CBC at home. The published abstract also does not report the absolute cells-per-microliter values defining the tertiles. A "high" tertile in people with established coronary disease could still fall within a laboratory reference range for someone else.

The remission result points in the same direction

A separate 2025 CORDIOPREV sub-study examined 183 participants who already had type 2 diabetes. Over five years without glucose-lowering medication, 73 participants achieved remission and 110 did not. The study used American Diabetes Association remission criteria: HbA1c below 6.5% and fasting plasma glucose below 126 mg/dL, sustained for at least two years.

In that cohort, baseline absolute neutrophil count and several derived measures—neutrophil-to-lymphocyte, neutrophil-to-erythrocyte, neutrophil-to-HDL, and neutrophil-to-bilirubin ratios—predicted remission status. The Mediterranean-versus-low-fat analysis also reported a greater reduction in neutrophil count and a higher remission rate in the Mediterranean-diet arm.

This finding extends the first analysis from prevention to remission, but it does not prove that lowering neutrophils reverses diabetes. In the prevention analysis, change in neutrophil count in the Mediterranean-diet arm correlated inversely with an insulin-sensitivity index (R = −0.31, P = .019). Correlation can identify a useful marker; it cannot establish which biological change came first.

The remission study is also small once investigators divide 183 people into dietary arms, remitters, non-remitters, and multiple biomarker-ratio analyses. Small subgroups and multiple comparisons can produce results that fail to hold up elsewhere. The analysis did not explicitly control weight change as a primary covariate, which matters a great deal for diabetes remission.

A vascular result makes the pattern harder to ignore

The same research group found a related result in a third CORDIOPREV analysis. In participants with coronary heart disease, the Mediterranean diet, but not the low-fat diet, reduced neutrophil counts over follow-up and was associated with lower carotid intima-media thickness, or CIMT. CIMT is an ultrasound marker of carotid artery wall thickness, not a heart attack or stroke outcome.

The carotid study supports the possibility that immune activity links metabolic and vascular disease. But the neutrophil-CIMT relationship remains correlational. It cannot tell us whether neutrophils drove arterial change, reflected a change in adiposity or diet quality, or moved alongside another process.

The diet recommendation is stronger than the neutrophil hypothesis

Mediterranean-style eating does not depend on this biomarker theory for its case. A dose-response meta-analysis of 19 prospective cohorts, including more than 140,000 participants, found that each two-point increase in Mediterranean-diet score was associated with about a 13% lower relative risk of incident type 2 diabetes (RR 0.87). The cohort data support a graded association across populations, though observational studies cannot fully remove differences in lifestyle, income, activity, or body weight.

Randomized-trial evidence supports metabolic benefits as well. A 2025 meta-analysis of randomized controlled trials found that Mediterranean diets improved HbA1c, BMI, lipid profiles, and blood pressure in people with type 2 diabetes compared with control diets. Another 2025 meta-analysis of controlled trials found that Mediterranean diets supplemented with olive oil reduced serum inflammatory and endothelial biomarkers compared with low-fat diets. Neither review establishes absolute neutrophil count as the mediator of those benefits.

A Mediterranean pattern generally emphasizes vegetables, fruit, legumes, whole grains, nuts, extra-virgin olive oil, fish, and limited highly refined foods. It is a dietary pattern, not a neutrophil-lowering prescription. The best evidence supports it as a durable way to improve cardiometabolic risk factors, not as a personalized immune treatment selected by one CBC value.

Weight loss and the gut microbiome offer competing explanations

For diabetes remission, energy balance may explain much of the result. A 2022 umbrella review and systematic review concluded that weight loss and caloric restriction are the most consistent drivers of remission across dietary approaches. Very-low-calorie and low-carbohydrate interventions can produce remission despite having little in common with Mediterranean diets in polyphenol or omega-3 content. A 2024 systematic review of food-based strategies reached a similar conclusion: no dietary pattern showed clear superiority after accounting for energy balance.

That does not erase the CORDIOPREV findings. It means a Mediterranean diet could lower inflammation, help people lose weight, change food quality, or do all three. If participants in the Mediterranean arm lost more weight, weight loss could plausibly explain both lower neutrophils and greater remission. CORDIOPREV did not settle that causal question.

The gut microbiome is another plausible route. A 2024 systematic review and meta-analysis linked Mediterranean and plant-based dietary interventions with microbiota changes and glycemic outcomes in people with prediabetes or type 2 diabetes. Separate crossover trials in adults with metabolic syndrome found Mediterranean-diet-related changes in gut microbiota, metabolites, glucose, insulin, and insulin resistance, including this randomized crossover trial. CORDIOPREV did not measure microbiota alongside neutrophils, so it cannot rank microbiome effects, weight change, and immune changes in a causal chain.

What to do with a high neutrophil count

Use it as a conversation starter, not a diabetes test. A persistent elevation deserves clinical context: recent infection, inflammatory disease, smoking, medication use, other CBC results, and symptoms all matter. HbA1c, fasting glucose, body weight, blood pressure, lipids, and—in appropriate settings—CRP provide more direct metabolic context.

• Choose a Mediterranean-style diet because its cardiometabolic benefits have been replicated beyond CORDIOPREV.
• If you have type 2 diabetes and want remission, address calorie intake and sustainable weight loss alongside food quality. They are not competing chores.
• Do not treat a normal or elevated neutrophil count as a personalized diet assignment. No independently validated cutoff supports that use.
• If your clinician repeats a CBC during lifestyle changes, view neutrophils as one inflammatory marker among many, not proof that a diet is repairing insulin resistance.

CORDIOPREV offers a coherent hypothesis: baseline immune tone may influence metabolic response to diet. It has not yet shown that neutrophils are the gatekeeper, or that changing the count causes diabetes prevention or remission.

The practical verdict is refreshingly unglamorous. Mediterranean eating is well supported; weight loss remains central for remission when weight reduction is appropriate; and neutrophil count is a promising research signal in people with coronary heart disease, awaiting replication before it earns a place in routine diabetes prediction.